Invivogen
Menu

Mouse anti-mouse mAbs

Benefits of mouse anti-mouse mAbs
Benefits of mouse anti-mouse mAbs

Recombinant monoclonal antibodies for in vivo use

InvivoGen offers an expanding collection of InvivoFit recombinant mouse anti-mouse monoclonal antibodies (mAbs). These mAbs were engineered to limit their immunogenicity for a constant efficacy upon repeated injections in mice. Our collection includes mAbs targeting immune checkpoints such as PD-1, and tumor-associated antigens such as gp75. These mAbs are produced in Chinese hamster ovary (CHO) cells and are provided in an  InvivoFit grade, a high-quality standard specifically adapted to in vivo studies.

 

Features of InvivoFit™ mouse anti-mouse mAbs:

  • Sequence is 85% to 100% murine
  • Guaranteed sterile, endotoxin level: <1 EU/mg
  • Suitable for parenteral delivery in mice (azide-free) 
  • Low aggregation: < 5%
  • Produced in both animal-free facilities and defined media

 

InvivoGen's recombinant mouse anti-mouse mAbs include antibodies for which the sequence is either 100% mouse origin (constant and variable regions), or ~85% mouse origin (constant regions) and ~15% non-mouse origin (variable regions). The minimal use of xenogeneic sequences limits the immunogenicity of the mAb [1]. Indeed, a major pitfall encountered in murine in vivo studies aimed at evaluating the activity of a mAb upon repeated injections is the decrease and loss of antibody performance if its sequence is not of mouse origin. Repeated injections in mice lead to anti-species antibody generation by the host (e.g. anti-rat antibodies if the mAb was produced in rats). This occurrence increases as the fraction of non-mouse sequences increases. Replacing xenogeneic sequences with mouse sequences reduces antibodies immunogenicity, and thus helps retain their activity in vivo.

 

References:

1. Brüggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157. 

 

 

Customer Service
& Technical Support
Contact us
Shopping cart is empty